The company announced that its Board of Directors approved a 1-for-1split of the company's common stock, which will be effected in the form of a 100% stock dividend. The stock dividend will be distributed Nov. 30 to stockholders of record as of Nov. 9. Haemonetics' common stock will begin trading on a post-split basis on the New York Stock Exchange on Dec. 3. The company expects that this split will make its shares more accessible, increase its shareholder base and improve its market liquidity.
- Stocks & Offerings
- common stock